Sanofi: Wearables are a core part of our digital trials strategy

Sanofi is looking to wearable devices to improve the way it collects data and increase the effectiveness and efficacy of its clinical trial management.

The pharma firm has partnered with service company Parexel, work that begins with a proof of concept study of patient sensors.

Lionel Bascles, global head of clinical sciences and operations at Sanofi, said: “Our objective is to demonstrate the relevance of data collected remotely and the overall feasibility of utilising wearables in clinical trials.

“Wearables are a core component of Sanofi’s digital trials strategy, and represent an important approach to automate patient processes using the latest technologies to bring new therapies to patients sooner.”

Sanofi and Parexel are collaborating on a pilot study of the latter’s patient sensor solution that they hope will demonstrate the scientific and medical viability of using wearables in a clinical trial setting.

In particular they will examine how data from several wearables can be combined into “a single, scalable data system”.

Parexel Informatics president Xavier Flinois said: “We believe the use of wearables to collect data from trial participants represents a breakthrough in the digital transformation within the industry.”